我院未足月胎膜早破患者宫缩抑制剂的临床应用与分析  

Clinical application and analysis of tocolytic drugs for preterm premature rupture of membranes patients in our hospital

作　　者：王萌萌[1] 庞艳玉[1] 王先利[1] 杨振宇[1] 

机构地区：[1]复旦大学附属妇产科医院药剂科,上海200011

出　　处：《中国临床药学杂志》2016年第5期303-306,共4页Chinese Journal of Clinical Pharmacy

摘　　要：目的探讨在未足月胎膜早破（PPROM）患者中宫缩抑制剂的临床应用及效果。方法回顾性分析我院106例PPROM孕产妇及其围产儿临床资料，对宫缩抑制剂应用情况、不同类型PPROM患者的妊娠结局和围产儿结局进行比较和评价。结果我院PPROM患者所用宫缩抑制剂以利托君为主，但受其不良反应所限，用量占比已明显下降。宫缩抑制剂对于孕24～33＋6周患者48h内有效率在64％以上，并对改善妊娠结局，降低流产、早产率起到一定作用。近足月PPROM患者所娩新生儿出现新生儿窒息及死亡概率明显低于远离足月PPROM，差异具有统计学意义（P〈0．05）。结论我院针对PPROM患者应用宫缩抑制剂基本规范。合理选择并应用宫缩抑制剂可在一定范围内推迟分娩，争取促胎肺成熟时间，有效改善妊娠结局和围产儿结局。AIM To explore the clinical application and intervention effect of tocolytic drugs in the treatment of preterm premature rupture of membranes （PPROM）. METHODS A retrospective analysis about the clinical data of 106 pregnant women with PPROM and their babies was taken to compare and evaluate application of tocolytic drugs, pregnan- cy outcome and perinatal fetus outcome in different types of PPROM patients. RESULTS Ritodrine was the main tocolytic drug used for the PPROM patients in our hospital, but had a high rate of adverse drug reactions, which led to a significant decline of use proportion. The effective rate of tocolytic drugs could be over 64 % in 48 h when PPROM hap- pened in 24 - 33 ~ 6 weeks, and played a certain action on improving the pregnancy outcome, decreasing the rate of mis- carriage and premature. The probability of neonatal asphyxia and death happened in PPROM patients near term was sig- nificantly less than that away from term （ P 〈 0.05）. CONCLUSION Reasonable selection and application of tocolytic drugs to delay the delivery as far as possible can buy time for promoting fetal lung maturation, improve the pregnancy out- come and perinatal outcome effectively.

关 键 词：未足月胎膜早破 宫缩抑制剂 妊娠结局 围产儿结局 

分 类 号：R714.433[医药卫生—妇产科学]